Menu
Menu
The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.
We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.
Key Discussion Points:
Learning Objectives:
June 10, 2026 | 1:00PM SGT
Liquid biopsy (LBx) has emerged as a non-invasive genomic profiling approach to guide decision-making and to monitor resistance in cancer, especially when access to tumor tissue is limited. However, one of the key challenges of LBx is distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants, which can occur in biologically relevant genes and confound variant interpretation. In this webinar, Dr. Keller and Dr. Fares (IUCT Oncopole, France) will explore real-world cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform decisions. The decentralized liquid biopsy solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations.
By attending this session, you will gain:
June 3, 2026 | 1:00PM SGT
Clinical Genomics at MSK
Michael Berger, Ph.D
Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, MSKCC
Dr. Berger’s session will explore the development of MSK-IMPACT and MSK-ACCESS, MSK’s comprehensive genomic profiling andcfDNA analysis programs. These initiatives address the need for large-scale molecular profiling across diverse tumor types. A keyfocus will be the role of matched tumor-normal sequencing in reducing biological false positives, ensuring true somatic variantsare accurately identified while enabling seamless integration of germline analysis. Dr. Berger will also discuss how SOPHiAGENETICS has become a key collaborator, empowering MSK to expand the accessibility of precision oncology globally throughscalable, cloud-based solutions.
Advancing Precision Oncology with a Matched Tumor-Normal Approach: Insights from the Clinic
Anita Bowman, M.S,
Associate Director of Clinical Bioinformatics, MSKCC
Anita Bowman will delve into the clinical applications of MSK-IMPACT and MSK-ACCESS at MSK, illustrating how thesetechnologies meet the personalized needs of patients. Through real-world case studies, she will showcase how a matchedtumor-normal approach has enhanced diagnosis and treatment planning. This methodology not only minimizes false positivesbut also identifies clonal hematopoiesis of indeterminate potential (CHIP) and resistance mechanisms, improving precision intreatment strategies.
Learning Objectives
May 20, 2026 | 1:00PM SGT
Comprehensive genomic profiling (CGP) using a matched tumor-normal approach can help improve somatic detection rate and streamline interpretation.
MSK-IMPACT® powered with SOPHiA DDM™ is a CGP solution that leverages matched tumor-normal sequencing to filter germline variants and may also identify clonal hematopoietic variants, revealing mutations of true somatic origin. The end-to-end application combines the clinical expertise of Memorial Sloan Kettering Cancer Center (MSK) with the robust analytics of SOPHiA DDM™.
Join us and MSK to:
May 27, 2026 | 1:00PM SGT
MSK-ACCESS® powered with SOPHiA DDM™ offers an innovative and decentralized solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform. This application aims to address the global inequalities in comprehensive cancer care.
Watch to hear about the collaborative efforts of SOPHiA GENETICS and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™. In this session, you will
June 3, 2026 | 1:00PM SGT
Traditional genomic analysis often requires sequential testing or a “one-size-fits-all” comprehensive genomic profiling (CGP) panel, leading to time-consuming workflows and increased costs. MSK-IMPACT® Flex powered with SOPHiA DDM™ is a modular, end-to-end CGP solution built on the expertly designed content of MSK-IMPACT®. The flexible design enables agile analysis and high-resolution profiling of complex biomarkers (including TMB, MSI, HRD, and gene- and exon-level CNVs) from DNA capture, RNA capture, and low-pass whole genome sequencing.
In this session, you will:
Speakers:
Dr. Rehan Mujeeb Faridi, PhD, HCLD/CC (ABB), Director of Molecular Diagnostics, OncoHelix
Lina Li, Director, Product Management, Application, SOPHiA GENETICS
Izabela Matyszczak, Technical Product Management Expert, SOPHiA GENETICS
June 17, 2026 | 1:00 PM SGT
Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers. In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay.
Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.
In this session you will:
Delivering reliable exome results at scale demands more than sequencing and data analytics performance alone. It requires an integrated, standardized workflow that carries data seamlessly from library preparation through to confident variant interpretation. Yet many research laboratories continue to struggle with fragmented pipelines, inconsistent quality, and interpretation bottlenecks that slow the time to answers.
In this webinar, Mgr. Helena Paszeková from GHC Genetics will showcase how her laboratory implemented an end-to-end exome workflow into their daily operations. Drawing on her experience managing high testing volumes across rare and inherited disorders, she will describe how integrating ELEMENT AVITI™ sequencing with the SOPHiA DDM™ Clinical Exome v3 and Whole Exome v2 Solutions has transformed efficiency, consistency, and turnaround times at GHC Genetics.
Through concrete examples, attendees will see how a unified, standardized approach drives reliable results and can accelerate the path from sequencing data to clinical insights.
Key takeaways from the webinar include:
Speakers:
Accurate and comprehensive genomic insights are increasingly essential for the diagnosis, classification, and risk stratification of myeloid malignancies — spanning single nucleotide variants, gene fusions, and large chromosomal aberrations. Yet consolidating these layers of genomic data into routine clinical workflows remains a significant bottleneck for many laboratories.
In this webinar, join Cecilia Lang, Biochemist and Head of Cytogenetics at Laboratorio de Especialidades Bioquímicas (LEB, Argentina), and Brandon Bullough, Product Marketing Director at SOPHiA GENETICS, as they explore how NGS-based molecular profiling with the SOPHiA DDM™ Myeloid Solution v2 (MYS2) can consolidate laboratory workflows and accelerate time-to-insights in the analysis of myeloid malignancies.
Brandon Bullough will open with an overview of SOPHiA DDM™ MYS2, tracing the need that drove its development and what sets it apart as a comprehensive myeloid solution. Cecilia Lang will then share her team's real-world experience implementing SOPHiA DDM™ MYS2 at a cytogenetics-focused reference center in Latin America — including its practical impact on day-to-day workflows and her perspective on where the field is headed.
Learning objectives
Speakers
Cecilia Lang
Head of Cytogenetics and FISH
Laboratorio de Especialidades Bioquimicas, LEB
Andrea Bender
Head of Molecular Biology
Laboratorio de Especialidades Bioquimicas, LEB
Brandon Bullough
Product Marketing Director, Blood Cancers
SOPHiA GENETICS
Real-world insights from Hospital Mário Penna
In this webinar, we explore how the MaxCare Program supported Hospital Mário Penna in implementing and adopting into routine two new NGS applications for the investigation of myeloid and lymphoid malignancies. The program empowered the local team to gain confidence in their results while assessing and establishing the analytical performance of the workflow.
Hospital Mário Penna shares their experience with SOPHiA GENETICS’ end-to-end implementation support, covering every step of the process—from strategic consultation and on-site training to data generation and analytical performance evaluation by the data science team, all tailored to the laboratory’s real-world context. The session concludes with the transition of these tests into routine practice, illustrated through two case studies: one in acute myeloid leukemia (AML) and the other in chronic lymphocytic leukemia (CLL).
Speakers:
Carolina Pereira de Souza Melo, PhD,
Researcher, Basic and Translational Oncology Research Laboratory, Instituto Mário Penna, Brazil
Gabrielle Martins Gonçalves, MSc,
SOPHiA GENETICS Implementation Scientist LATAM
Day: May 14th
Time: 11h BR/AR l 10h CL l 9h CO/PA l 8h MX/CR
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.